• Age: ≥ 18 to ≤ 40 years

• Diagnosis of Polycystic Ovary Syndrome (PCOS) according to Rotterdam criteria: Infertility associated with chronic anovulation or oligomenorrhea, AND EITHER:

‣ 1. Ultrasonographic evidence of PCOS (ovarian volume ≥ 10ml and/or ovarian antral follicle count per ovary ≥ 20) OR 2.2. Evidence of hyperandrogenaemia: either clinical (hirsutism defined as mFG level ≥ 4-6 depending on ethnicity) or biochemical (raised serum concentration of androgens (testosterone ≥ 2.5nmol/l, or FAI \> 4)

• At least one ovary with ovarian volume ≥ 10ml

• Ovarian accessibility: determined by ability to bring transvaginal ultrasound transducer into close proximity to ovaries

• Failure to respond to first-line pharmacological treatment or is contraindicated for or decline such treatment.

• At least one patent fallopian tube and normal uterine cavity as determined by sonohysterogram, hysterosalpingogram, or hysteroscopy/laparoscopy within the last 3 years

• Willing to comply with Clinical Investigation Plan-specified follow-up evaluation

• Ability to understand study requirements and has sufficient fluency in one of the IRB-approved written translation of the Patient Information and Informed consent form

• Signed informed consent

⁃ Normal sperm parameters based on WHO 2010 criteria (concentration ≥ 15 million/mL, total motility ≥ 40%, normal morphology ≥ 4%) within the last year

⁃ Ability to have regular vaginal intercourse during the study

⁃ No previous sterilization procedures (vasectomy, tubal ligation) that have been reversed